Sign In
Buy GTHX
$7.15
+0 (+0%)
At Close: Dec 16, 2024
Why Tupperware Brands Shares Dipped Around 42%; Here Are 89 Biggest Movers From Yesterday
09:40am, Thursday, 03'rd Nov 2022 Benzinga
Gainers
Starry Group Holdings, Inc. (NYSE: STRY) rose 55.6% to close at $0.28 on Wednesday after reporting Q3 results.
Benefitfocus, Inc. (NASDAQ: BNFT) shares surged 48.2% to settle at $10.36 on We
Why Benefitfocus Shares Are Trading Higher By Around 48%? Here Are 64 Stocks Moving In Wednesday's Mid-Day Session
05:28pm, Wednesday, 02'nd Nov 2022 Benzinga
Gainers
Starry Group Holdings, Inc. (NYSE: STRY) gained 56% to $0.2808 after reporting Q3 results.
Benefitfocus, Inc. (NASDAQ: BNFT) shares jumped 47.8% to $10.33 after the company announced it will
G1 Therapeutics Provides Third Quarter 2022 Financial Results and Operational Highlights
10:30am, Wednesday, 02'nd Nov 2022 GlobeNewswire Inc.
- Achieved $23.6 million in Total Revenue in the Third Quarter of 2022 Including $8.3 million in Net Revenue from Sales of COSELA® (trilaciclib) -
Initial Results from Phase 2 Trial Demonstrate Potential of Trilaciclib to Reduce Adverse Events Related to an Antibody Drug Conjugate (ADC)
10:28am, Wednesday, 02'nd Nov 2022 GlobeNewswire Inc.
- Data Suggest On-Target Effect of Trilaciclib May Reduce Rates of Myelosuppression, Diarrhea, and Potentially Alopecia Associated with Sacituzumab Govitecan-Hziy - - Data Suggest On-Target Effect of
G1 Therapeutics (GTHX) Reports Q3 Loss, Tops Revenue Estimates
09:02am, Wednesday, 02'nd Nov 2022
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 7.81% and 4.14%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09:40pm, Tuesday, 01'st Nov 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exerc
Is G1 Therapeutics (GTHX) Stock Outpacing Its Medical Peers This Year?
01:40pm, Friday, 28'th Oct 2022 Zacks Investment Research
Here is how G1 Therapeutics (GTHX) and HealthEquity (HQY) have performed compared to their sector so far this year.
Is G1 Therapeutics (GTHX) Stock Outpacing Its Medical Peers This Year?
11:18am, Friday, 28'th Oct 2022
Here is how G1 Therapeutics (GTHX) and HealthEquity (HQY) have performed compared to their sector so far this year.
G1 Therapeutics Announces Investigator Initiated Study of Trilaciclib and Lurbinectedin in Patients with Extensive Stage Small Cell Lung Cancer
01:26pm, Wednesday, 26'th Oct 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 26, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it is supporting a Phase 2 investiga
G1 Therapeutics: Catalysts Stacking
03:22pm, Thursday, 20'th Oct 2022
Though no longer having Boehringer as its launch partner, G1 Therapeutics, Inc. posted good sales traction for Cosela. There are several big data releases going into the year-end and next year that ca
G1 Therapeutics to Release Third Quarter 2022 Financial Results and Provide Business Update on November 2, 2022
04:30pm, Wednesday, 19'th Oct 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 19, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corpor
G1 Therapeutics to Release Third Quarter 2022 Financial Results and Provide Business Update on November 2, 2022
12:30pm, Wednesday, 19'th Oct 2022
RESEARCH TRIANGLE PARK, N.C., Oct. 19, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporat
Is G1 Therapeutics (GTHX) Outperforming Other Medical Stocks This Year?
01:40pm, Wednesday, 12'th Oct 2022 Zacks Investment Research
Here is how G1 Therapeutics (GTHX) and HealthEquity (HQY) have performed compared to their sector so far this year.
Is G1 Therapeutics (GTHX) Outperforming Other Medical Stocks This Year?
12:04pm, Wednesday, 12'th Oct 2022
Here is how G1 Therapeutics (GTHX) and HealthEquity (HQY) have performed compared to their sector so far this year.
G1 Therapeutics Completes Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Triple Negative Breast Cancer (TNBC)
10:30am, Monday, 10'th Oct 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 10, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the last patient has been randomized
